Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol
- PMID: 571916
- DOI: 10.1021/jm00193a003
Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol
Abstract
Several analogues of the neuroleptic agent butaclamol, having modifications in the ring E region of the molecule, have been synthesized. Pharmacological evaluation identified two of the analogues as being equipotent to butaclamol, namely, anhydrobutaclamol (8) and deoxybutaclamol (9a). The molecular structures of both the active and inactive analogues were analyzed and the results have been used for mapping the central dopamine receptor. The existence of a previously proposed lipophilic accessory binding site on the receptor macromolecule has been confirmed. Its minimum dimensions, as well as its locus with respect to the primary binding sites, have been defined. A receptor model incorporating the above features is proposed.
Similar articles
-
Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.J Med Chem. 1979 Jul;22(7):768-73. doi: 10.1021/jm00193a004. J Med Chem. 1979. PMID: 571917
-
Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.J Med Chem. 1978 Dec;21(12):1225-31. doi: 10.1021/jm00210a011. J Med Chem. 1978. PMID: 31480
-
Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.J Med Chem. 1978 Jul;21(7):694-8. doi: 10.1021/jm00205a021. J Med Chem. 1978. PMID: 27637
-
Dopamine receptors in the central nervous system.Fed Proc. 1978 Feb;37(2):131-6. Fed Proc. 1978. PMID: 414936 Review.
-
Is conformational analysis a key to solve the structure--activity problem of neuroleptics?Pharmazie. 1986 Apr;41(4):277-81. Pharmazie. 1986. PMID: 2425381 Review. No abstract available.